About DalCor Pharmaceuticals
DalCor Pharmaceuticals is a private company based in Sarasota, Florida. It has reported $65,809,935 raised in three offerings on Form D since May 2016.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Aug 28, 2026 | $6,958,236fully sold | 8 | $869K | EquityRule 506(b) | Form D ↗ |
| May 12, 2020 | May 27, 2020amended Sep 14, 2020 | $3,851,699fully sold | 4 | $962K | Equity, DebtRule 506(b) | Form D/A ↗1 earlier filing |
| Apr 29, 2016 | May 13, 2016amended May 12, 2017 | $55,000,000of $110.0M target | 47 | $1.1M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $65,809,935 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on DalCor Pharmaceuticals's Form D filed Aug 28, 2026.
Earlier filings also listed Donald Black (director, last listed Sep 2020), D. Michael Dixon (director, last listed Sep 2020), Thomas Birch (director, last listed May 2017), Rody Yared (director, last listed May 2017), Robert McNeil (executive officer, director and promoter, last listed May 2017), Mark Smith (director, last listed May 2017), Louise Proulx (executive officer, last listed May 2017) and Laurence Rulleau (director, last listed May 2017).